A Multicenter, Double-Blind, Placebo-Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions
- Acronyms SIGNAL
- Sponsors BioMarin Pharmaceutical; Merck KGaA
- 13 May 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 21 Nov 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
- 18 Nov 2013 New trial record